Veralox Therapeutics Announces FDA Orphan Drug Designation for VLX-1005
Share Article
The U.S. Food and Drug Administration has granted Orphan Drug Designation for VLX-1005 for the treatment of heparin induced thrombocytopenia.
“This is a significant regulatory milestone for our company, and in the development of this investigational new drug product and recognition of the clear unmet medical need for patients who suffer from this devastating disease.” - Jeffrey W. Strovel, PhD., CEO, Veralox Therapeutics FREDERICK, Md. (PRWEB) January 27, 2021 Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for VLX-1005 for the treatment of heparin induced thrombocytopenia (HIT).